Elsevier

Life Sciences

Volume 40, Issue 25, 22 June 1987, Pages 2429-2436
Life Sciences

Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action

https://doi.org/10.1016/0024-3205(87)90758-2Get rights and content

Abstract

A considerable body of biochemical and neurophysiological evidence implicates GABA in anxiety and in benzodiazepine action. The present article surveys the behavioral effects of GABA agonists and their interactions with drugs acting at the benzodiazepine receptor in animal anxiety paradigms. Certain GABA agonists, notably valproate, simulate many behavioral actions of benzodiazepines. Moreover, several behavioral studies of the interaction of GABA agonists with benzodiazepines support the hypothesis of a benzodiazepine receptor complex with one or more GABA, benzodiazepine and probably other binding sites. However, there are also a number of anomalous findings of GABA agonist action alone and in combination with benzodiazepines. It is argued that these paradoxical results can better be accounted for in terms of the receptor complex and the distribution of the drugs, rather than by suggesting that the anxiolytic actions of benzodiazepines are not mediated by GABA systems. The potential clinical usefulness of GABA agonists in anxiety is commented upon.

References (58)

  • A.S. Lippa et al.

    Pharmacol. Biochem. Behav.

    (1978)
  • D.J. Sanger

    Life Sci.

    (1985)
  • R.A. Shephard

    Neurosci. Biobehav. Rev.

    (1986)
  • R. Dantzer

    Biobehav. Rev.

    (1977)
  • D. Treit

    Neurosci. Biobehav. Rev.

    (1985)
  • N.C. Tye et al.

    Neuropharmacology

    (1979)
  • H.M. Hodges et al.

    Behav. Neurol. Biol.

    (1984)
  • M.H. Thiebot et al.

    Neuropharmacology

    (1980)
  • H. Lal et al.

    Brain Res. Bull.

    (1979)
  • H. Lal et al.

    Neuropharmacology

    (1980)
  • S. Liljequist et al.

    Life Sci.

    (1984)
  • R.A. Shephard et al.

    Neuropharmacology

    (1984)
  • M.K. Ticku et al.

    Brain Res.

    (1981)
  • J.D. Gent et al.

    Brain Res.

    (1980)
  • S.J. Cooper et al.

    Neurosci. Biobehav. Rev.

    (1985)
  • B.R. Cooper et al.

    Life Sci.

    (1980)
  • S. Huot et al.

    Pharmacol. Biochem. Behav.

    (1982)
  • L. Grandison et al.

    Neuropharmacology

    (1977)
  • J. Kelly et al.

    Pharmacol. Biochem. Behav.

    (1979)
  • J.E. Morley et al.

    Life Sci.

    (1981)
  • J. Kelly et al.

    Pharmacol. Biochem. Behav.

    (1977)
  • J. Kelly et al.

    Physiol. Behav.

    (1979)
  • S.V. Vellucci et al.

    Eur. J. Pharmacol.

    (1983)
  • M. Morag et al.

    Life Sci.

    (1982)
  • J. Feldon et al.

    Pharmacol. Biochem. Behav.

    (1983)
  • K.G. Lloyd et al.

    Pharmacol. Biochem. Behav.

    (1983)
  • L.J. Herberg et al.

    Pharmacol. Biochem. Behav.

    (1983)
  • J. Sepinwall et al.

    Brain Res. Bull.

    (1980)
  • N.R. Oakley et al.

    Neuropharmacology

    (1984)
  • Cited by (37)

    • Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study

      2008, European Psychiatry
      Citation Excerpt :

      Antiepileptic drugs may have a place in the treatment of anxiety disorders; however, further investigation is warranted to determine in what circumstances they should be used as monotherapy or as augmenting agents in individuals who are partially or non-responsive to conventional therapy [23,40]. A number of preclinical studies have demonstrated that valproate and other GABA agonists have anxiolitic properties [6,7,10,12,15,24,31,34,36,37]. Clinical reports [1,9,14,20–22,25,28,33,35,39,43] suggest that valproate may have therapeutic effects in the treatment of bipolar depressive, anxiety (panic, social phobia and posttraumatic stress disorders) and psychotic disorders; alcohol withdrawal and dependence; tardive dyskinesia; agitation associated with dementia; and borderline personality disorders.

    • The neurobiology and control of anxious states

      2003, Progress in Neurobiology
      Citation Excerpt :

      At variance with these observations, upon acute administration, in a time-dependent fashion, angiotensin II elicited a delayed “rebound” reduction in anxiety, and not all studies with AT1 antagonists have observed anxiolytic effects (Gard, 2002). The role of angiotensin II in the control of anxious states may, thus, be complex, reflecting multiple and contrasting roles of AT1 and AT2 receptors (Shepherd et al., 1996; Okuyama et al., 1999b; Gard, 2002). Indeed, mice lacking AT2 receptors showed heightened anxiety-like behaviour, possibly mediated (indirectly) via actions of NA at α1-adrenoceptors in the amygdala (Section 4.1.5) (Ichiki et al., 1995; Walther et al., 1999; Okuyama et al., 1999b).

    • Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism

      2001, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      However, the equivocal effects of specific GABAA receptor manipulations in animal models of anxiety (e.g. Sanger, 1985; Shephard, 1986, 1987) have led some authors to question the relevance of this particular molecular mechanism to the anxiolytic properties of benzodiazepines (e.g. Agmo et al., 1991; Bartholini, 1985; Dalvi and Rodgers, 1996; Dalvi and Rodgers, 1999; Paredes and Agmo, 1992; Polc, 1991; Shephard, 1986, 1987). While some GABAergic compounds, such as valproic acid (VPA, GABA-T inhibitor) and picrotoxin (PX, noncompetitive GABAA receptor antagonist), produce consistent anti- and proanxiety effects across a wide range of animal models (e.g. Barros et al., 1992; Cannizzaro et al., 1987; Corbett et al., 1991; Corda and Biggio, 1986; Dalvi and Rodgers, 1996; de Angelis, 1992; File and Lister, 1984; Prado de Carvalho et al., 1983; Quintero et al., 1985a,b; Sanger, 1985; Shephard, 1987; Shephard and Hamilton, 1989; Shimada et al., 1992; Simiand et al., 1984; Soubrie et al., 1979; Stutzmann et al., 1987), others are either limited in efficacy or produce nonselective behavioural effects. Among the latter compounds, GABA-T inhibitors, amino-oxyacetic acid (AOAA) and vigabatrin, as well as GABAA receptor agonists, muscimol, isoguvacine and 4,5,6,7-tetrahydroisoxazolo[4,5]pyridin-3-ol (THIP) have generally been found to exert anxiolytic-like effects in unconditioned models such as the social interaction and plus-maze tests (Corbett et al., 1991; Dalvi and Rodgers, 1996; Nastiti et al., 1991; Rodgers and Dalvi, 1997; Sayin et al., 1992; Sherif et al., 1994; Sherif and Oreland, 1994; Vivian et al., 1997), but to produce relatively nonspecific effects in conditioned models such as Geller and Vogel conflict (Agmo et al., 1991; Cook and Sepinwall, 1980; Corbett et al., 1991; Gardner and Piper, 1982; Hodges and Green, 1984; Hodges et al., 1981; Rasmussen et al., 1981; Shephard et al., 1990; Thiebot et al., 1979).

    View all citing articles on Scopus
    View full text